The 2nd Edition of the International Classification of Sleep Disorders (ICSD-2), in the category of hypersomnia of central origin, subdivides narcolepsy into two groups: narcolepsy with cataplexy (NA-CA) and narcolepsy without cataplexy (NA w/o CA). NA w/o CA is characterized by excessive daytime sleepiness and abnormal manifestations of rapid eye movement (REM) sleep in common with NA-CA, but no cataplexy. Patients with NA w/o CA have frequent sleep-onset REM periods, as do those with NA-CA, as revealed by performance of the multiple sleep latency test. A population-based study suggested that the prevalence of NA w/o CA is 36% of the prevalence of narcolepsy as a whole, corresponding to a point prevalence of 0.02%.^[@bib1]^ NA-CA is tightly associated with *HLA-DQB1\*06:02* and orexin (hypocretin) deficiency. Almost all patients with NA-CA in many populations consistently carry *DQB1\*06:02*, while approximately 12% of Japanese, 25% of Caucasian and 38% of African American healthy individuals are *DQB1\*06:02*-positive.^[@bib2; @bib3; @bib4]^ Low levels of orexin A in cerebrospinal fluid (CSF) (\<110 pg/ml) are commonly observed in patients with NA-CA.^[@bib5],[@bib6]^ Regarding NA w/o CA, positivity of *HLA-DQB1\*06:02* (30--50%) is also higher than that in the general population,^[@bib7; @bib8; @bib9; @bib10]^ but less than that in NA-CA. However, only approximately 20% of patients with NA w/o CA have low levels of CSF orexin A,^[@bib6],[@bib10]^ indicating that the etiology of the majority of NA w/o CA is still unknown.

There have been a number of studies of *HLA* in NA-CA; results indicated that *HLA-DQB1* alleles other than *DQB1\*06:02* modulate susceptibility or resistance to NA-CA. *DQB1\*06:01* and *DQB1\*05:01* in the Korean and Japanese populations and *DQB1\*06:03* in European populations are protective against NA-CA,^[@bib2],[@bib7],[@bib11; @bib12; @bib13; @bib14]^ whereas individuals with *DQB1\*03:01* and *DQB1\*03:02* are at an increased risk.^[@bib2],[@bib7],[@bib11],[@bib13; @bib14; @bib15; @bib16; @bib17]^ In the present study, to test for associations of *HLA-DQB1* alleles in NA w/o CA, we performed an association study for *HLA-DQB1* in 160 Japanese patients with NA w/o CA and 1,418 control subjects.

Idiopathic hypersomnia (IHS) is a sleep disorder of presumed central nervous system origin that is associated with excessive daytime sleepiness consisting of prolonged non-REM sleep episodes. Daytime naps of IHS patients tend to be longer and less refreshing than those of NA-CA patients. IHS is a rare disease, representing 8:10 to 1:10 patients with NA-CA. This suggests that the prevalence of IHS approximates 0.005%.^[@bib18]^ The ICSD-2 describes two clinical forms of IHS by the difference in nocturnal sleep time: IHS with long sleep time (IHS-LST) and IHS without long sleep time (IHS w/o LST). The nocturnal sleep time of IHS-LST is prolonged to at least 10 h, while that of IHS w/o LST is either normal or slightly prolonged (less than 10 h). CSF orexin A levels in IHS are normal.^[@bib6]^ The cause and pathogenesis of IHS remain largely unknown. NA w/o CA and IHS w/o LST have several common characteristics except for REM-related symptoms. Distinguishing NA w/o CA and IHS w/o LST is impossible without the multiple sleep latency test to identify sleep-onset REM periods. According to the ICSD-2, the diagnosis is based on the number of sleep-onset REM periods, two or more in the former and less than two in the latter. In the present study, we tested whether *HLA-DQB1* alleles have an influence on susceptibility to IHS w/o LST and IHS-LST.

A total of 346 Japanese patients and 1,418 Japanese healthy controls were included in this study. NA w/o CA, IHS w/o LST and IHS-LST were diagnosed according to the ICSD-2 criteria. The patient groups consisted of NA w/o CA (*n*=160), IHS w/o LST (*n*=118) and IHS-LST (*n*=68). We utilized *HLA* data of healthy individuals, who have been previously studied for disease association analyses.^[@bib17],[@bib19],[@bib20]^ In addition, to assess genetic similarities between the above hypersomnia disorders and NA-CA, *HLA-DQB1* data from 664 patients with NA-CA were utilized.^[@bib17]^ All of the patients and controls were mainland Japanese and gave written informed consent. This study was approved by the local institutional review boards at participating institutions. Typing for the *HLA-DQB1* locus was performed by a Luminex Multi-Analyte Profiling system (xMAP) with WAKFlow HLA typing kits (Wakunaga Pharmaceutical, Wakunaga, Hiroshima, Japan). Comparisons of frequencies were performed using the Chi-square test or Fisher's Exact test as appropriate. To account for multiple testing, the significance level was adjusted by the number of *HLA* alleles with allele frequencies no less than 0.5% in controls (12 for *HLA-DQB1* alleles). The significance level was set to be *P*\<4.2×10^−3^ (0.05/12). If any of the four cells was zero, the Woolf-Haldane correction was applied (adding 0.5 to all cells). An association analysis controlling for the effects of *DQB1\*06:02* was needed to test the other *HLA-DQB1* alleles. Specifically, the analysis was performed using counts of the other *HLA-DQB1* alleles remaining after excluding allele counts of *DQB1\*06:02* from both cases and controls, which is the relative predispositional effects method.^[@bib21]^ Briefly, frequencies and ORs were calculated for the alleles carried by the non-*DQB1\*06:02* chromosomes. To determine whether there was a different allelic distribution between two groups, the overall frequency distribution of *HLA-DQB1* alleles in one group was compared with the distribution in another group by using the global Chi-square test with 12 degrees-of-freedom.

*HLA-DQB1* allele frequencies of 160 patients with NA w/o CA and 1,418 control subjects were determined, and are shown in [Table 1](#tbl1){ref-type="table"}. *DQB1\*06:02* was significantly associated with NA w/o CA (allele frequency: 16.6 vs. 7.8% in controls, *P*=1.1×10^−7^, OR=2.36). Regarding carrier frequencies for *HLA-DQB1*, 31.3% of the patients carried *DQB1\*06:02*, vs. 14.7% of controls (*P*=7.6×10^−8^, OR=2.64) ([Supplementary Table 1](#xob1){ref-type="supplementary-material"}). We tested whether there were other independent *HLA-DQB1* associations aside from *DQB1\*06:02* using the relative predispositional effect method.^[@bib21]^ *DQB1\*06:04* showed a marginal association (*P*=5.9×10^−3^, OR=1.80) ([Table 2](#tbl2){ref-type="table"}). However, the *P* value did not reach the threshold corrected for multiple comparisons. NA w/o CA was subdivided into *DQB1\*06:02*-positive and -negative groups for further analyses, because previous studies suggested that these two disease groups have different etiology, clinical characteristics and electroencephalographic findings.^[@bib10],[@bib22; @bib23; @bib24]^ The analyses were performed by controlling for the effects of *DQB1\*06:02* ([Table 2](#tbl2){ref-type="table"}). No significant association with *HLA-DQB1* alleles was found in *DQB1\*06:02*-positive NA w/o CA. *DQB1\*06:04* was nominally associated with *DQB1\*06:02*-negative NA w/o CA patients (*P*=5.6×10^−3^, OR=1.88).

Next, we tested whether *HLA-DQB1* allele distributions (except for *DQB1\*06:02*) in *DQB1\*06:02*-positive and -negative NA w/o CA patients showed similarities with those of NA-CA patients ([Table 2](#tbl2){ref-type="table"} and [Supplementary Figure 1](#xob1){ref-type="supplementary-material"}). The allele distribution of *DQB1\*06:02*-negative NA w/o CA was significantly different from that of NA-CA (*P*=5.8×10^−7^). On the other hand, no significant difference was observed in the distribution between *DQB1\*06:02*-positive NA w/o CA and NA-CA (*P*=0.97). When we focused on *HLA-DQB1* alleles with frequencies no less than 5% in *DQB1\*06:02*-positive NA w/o CA, all the ORs of the alleles were found in the same direction as those of NA-CA ([Table 2](#tbl2){ref-type="table"}). These results suggest that a common etiological pathway might exist for *DQB1\*06:02*-positive NA w/o CA and NA-CA, whereas *DQB1\*06:02*-negative NA w/o CA has a different etiological pathway from NA-CA. Orexin A in the CSF of typical NA-CA patients is known to be reduced or undetectable.^[@bib5],[@bib6]^ A minority of NA w/o CA patients have low concentrations of CSF orexin A levels, although a majority of NA w/o CA patients have normal concentrations;^[@bib6],[@bib10]^ thus, an etiologic heterogeneity in NA w/o CA is suggested. In addition, most of the NA w/o CA patients with low CSF orexin A are *DQB1\*06:02-*positive, as in NA-CA.^[@bib6],[@bib10]^ In contrast, *DQB1\*06:02* positivity of patients with normal CSF orexin A is not higher than that seen in the general population.^[@bib10]^ Therefore, the heterogeneity in NA w/o CA might be divided by *DQB1\*06:02* positivity, and *DQB1\*06:02-*positive NA w/o CA might have the same etiology as NA-CA from the view point of orexin deficiency. In addition, clinical characteristics and electroencephalographic findings have been reported to be different between *DQB1\*06:02*-positive and -negative NA w/o CA groups.^[@bib23],[@bib24]^ These findings correspond well to our result.

Patients with IHS w/o LST and IHS-LST were also typed for *HLA-DQB1* in the present study. *HLA-DQB1* allele and carrier frequencies are shown in [Table 3](#tbl3){ref-type="table"} and [Supplementary Table 2](#xob1){ref-type="supplementary-material"}, respectively. *DQB1\*06:02*, known to be associated with NA-CA and NA w/o CA, was not associated with IHS w/o LST or IHS-LST. Although *DQB1\*05:02* (*P*=6.3×10^−3^) and *DQB1\*03:01* (*P*=0.04) showed nominally significant associations with IHS-LST, there were no *HLA-DQB1* alleles that reached the threshold after correction for multiple comparisons. The similarity of *HLA-DQB1* allele distribution between NA-CA and IHS w/o LST or IHS-LST was tested after controlling for the effects of *DQB1\*06:02*, and significant differences were found: for IHS w/o LST: *P*=2.1×10^−4^ and for IHS-LST: *P*=2.2×10^−8^. Taken together, these results indicate that IHS w/o LST and IHS-LST are caused by different etiological genetic factors than those that give rise to NA-CA.

The International Classification of Sleep Disorders was recently revised for the 3rd Edition (ICSD-3). When we had recruited patient samples, the 2nd edition (ICSD-2) was used. Main differences between the ICSD-2 and ICSD-3 regarding NA w/o CA, IHS w/o LST and IHS-LST are as follows. The terminology has been changed from 'narcolepsy without cataplexy (NA w/o CA)' to 'narcolepsy type 2'. The concept of NA w/o CA and narcolepsy type 2 is almost the same. IHS w/o LST and IHS-LST were unified to 'idiopathic hypersomnia (IHS)' regardless of the extension of the sleep time. Therefore, we combined our IHS w/o LST and IHS-LST data to analyze the *HLA-DQB1* data as IHS ([Supplementary Tables 3 and 4](#xob1){ref-type="supplementary-material"}). As a result, no significant association was observed between each *HLA-DQB1* allele and IHS. Distribution of *HLA-DQB1* alleles in IHS was also significantly different from that of NA-CA, even after the effect of *DQB1-06:02* was controlled (*P*=8.6×10^−9^).

To conclude, the association of *DQB1\*06:02* in NA w/o CA was confirmed. Our results also suggested an immunological pathogenesis of *DQB1\*06:02-*positive NA w/o CA, which is similar to that of NA-CA. *DQB1\*06:02-*negative NA w/o CA, IHS w/o LST and IHS-LST may have a different etiology, which is not well understood.
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###### *HLA-DQB1* allele frequencies of patients with NA w/o CA

  *DQB1*     *NA w/o CA*   *(2n=320)*   *Control*   *(2n=2836)*   *OR*      P
  --------- ------------- ------------ ----------- ------------- ------ ----------
  *02:01*         1           0.3          11           0.4       0.81     1.00
  *03:01*        29           9.1          334         11.8       0.75     0.15
  *03:02*        27           8.4          264          9.3       0.90     0.61
  *03:03*        46           14.4         450         15.9       0.89     0.49
  *04:01*        42           13.1         374         13.2       0.99     0.97
  *04:02*        12           3.8          118          4.2       0.90     0.73
  *05:01*        22           6.9          191          6.7       1.02     0.92
  *05:02*         3           0.9          63           2.2       0.42     0.13
  *05:03*        10           3.1          106          3.7       0.83     0.58
  *06:01*        45           14.1         515         18.2       0.74     0.07
  *06:02*        53           16.6         220          7.8       2.36   1.1.E−07
  *06:03*         1           0.3          16           0.6       0.55     1.00
  *06:04*        28           8.8          160          5.6       1.60     0.03
  *06:09*         1           0.3          14           0.5       0.91     1.00

Abbreviations: NA w/o CA, narcolepsy without cataplexy; OR, odds ratio.

###### Frequencies of *HLA-DQB1* alleles after removal of *DQB1\*06:02* effects

  *DQB1 alleles*                                              *NA w/o CA*   *DQB1\*06:02 (+) NA w/o CA*   *DQB1\*06:02 (−) NA w/o CA*   *Control*   *NA-CA*                                                                                                
  ---------------------------------------------------------- ------------- ----------------------------- ----------------------------- ----------- --------- ------ ------ ------ --------- ------ ------ ---------- ---------- ------ ----- ------ ------ ----------
  *02:01*                                                          1                    0.4                          0.89                 1.00         0      0.0    2.38   1.00      1      0.5    1.08     1.00        11      0.4     5    0.9    1.78     0.22
  *03:01*                                                         29                   10.9                          0.83                 0.37         9      19.1   1.62   0.20     20      9.1    0.68     0.11       334      12.8   98    16.9   1.38   5.7.E−03
  *03:02*                                                         27                   10.1                          1.00                 0.99         6      12.8   1.30   0.47     21      9.5    0.94     0.80       264      10.1   107   18.4   1.97   2.5.E−09
  *03:03*                                                         46                   17.2                          1.00                 0.99         8      17.0   0.99   0.97     38      17.3   1.00     0.98       450      17.2   74    12.8   0.73     0.02
  *04:01*                                                         42                   15.7                          1.12                 0.53         9      19.1   1.42   0.35     33      15.0   1.06     0.78       374      14.3   112   19.3   1.43   1.2.E−03
  *04:02*                                                         12                    4.5                          1.00                 0.99         1      2.1    0.46   0.72     11      5.0    1.11     0.74       118      4.5    20    3.4    0.77     0.27
  *05:01*                                                         22                    8.2                          1.14                 0.58         2      4.3    0.56   0.58     20      9.1    1.27     0.33       191      7.3    20    3.4    0.48   1.5.E−03
  *05:02*                                                          3                    1.1                          0.46                 0.18         1      2.1    0.88   1.00      2      0.9    0.37     0.15        63      2.4    28    4.8    1.80   4.4.E−03
  *05:03*                                                         10                    3.7                          0.92                 0.81         1      2.1    0.51   1.00      9      4.1    1.01     0.98       106      4.1    21    3.6    0.79     0.31
  *06:01*                                                         45                   16.9                          0.83                 0.27         6      12.8   0.60   0.24     39      17.7   0.88     0.48       515      19.7   49    8.4    0.39   1.4.E−10
  *06:03*                                                          1                    0.4                          0.61                 1.00         0      0.0    1.66   1.00      1      0.5    0.74     1.00        16      0.6     1    0.2    0.25     0.26
  *06:04*                                                         28                   10.5                          1.80               5.9.E−03       4      8.5    1.43   0.50     24      10.9   1.88   5.6.E−03     160      6.1    42    7.2    1.10     0.58
  *06:09*                                                          1                    0.4                          0.70                 1.00         0      0.0    1.89   1.00      1      0.5    0.85     1.00        14      0.5     3    0.5    1.50     0.46
  Global *P* value versus NA-CA[b](#t2-fn2){ref-type="fn"}     4.3.E−06                                                                              0.97                          5.8E−07                            1.2.E−17                                  

Abbreviations: NA-CA, narcolepsy with cataplexy; NA w/o CA, narcolepsy without cataplexy; OR, odds ratio.

NA w/o CA: *n*=267, *DQB1\*06:02* (+) NA w/o CA: *n*=47, *DQB1\*06:02* (−) NA w/o CA: *n*=220, Control: *n*=2616, NA-CA: *n*=580.

*P* values were calculated for comparisons between disease and control groups.

The overall frequency distribution of *HLA-DQB1* alleles in NA-CA group was compared with that in another group using the global Chi-square test.

###### *HLA-DQB1* allele frequencies of patients with IHS w/o LST and IHS-LST

  *DQB1*     *IHS w/o LST*   *(2n=236)*                 *IHS-LST*   *(2n=136)*                     *Control*   *(2n=2836)*
  --------- --------------- ------------ ------ ------ ----------- ------------ ------ ---------- ----------- -------------
  *02:01*          0            0.0       0.52   1.00       0          0.0       0.90     1.00        11           0.4
  *03:01*         33            14.0      1.22   0.32       8          5.9       0.47     0.04        334         11.8
  *03:02*         26            11.0      1.21   0.39      10          7.4       0.77     0.44        264          9.3
  *03:03*         34            14.4      0.89   0.55      19          14.0      0.86     0.55        450         15.9
  *04:01*         35            14.8      1.15   0.48      13          9.6       0.70     0.22        374         13.2
  *04:02*          9            3.8       0.91   0.80       4          2.9       0.70     0.48        118          4.2
  *05:01*         19            8.1       1.21   0.44      11          8.1       1.22     0.54        191          6.7
  *05:02*          5            2.1       0.95   0.92       8          5.9       2.75   6.3.E−03      63           2.2
  *05:03*          8            3.4       0.90   0.79       8          5.9       1.61     0.20        106          3.7
  *06:01*         39            16.5      0.89   0.53      33          24.3      1.44     0.07        515         18.2
  *06:02*         16            6.8       0.86   0.59      12          8.8       1.15     0.65        220          7.8
  *06:03*          2            0.8       1.51   0.64       1          0.7       1.31     0.55        16           0.6
  *06:04*          9            3.8       0.66   0.24       8          5.9       1.05     0.91        160          5.6
  *06:09*          1            0.4       0.86   1.00       1          0.7       1.49     0.51        14           0.5

Abbreviations: IHS-LST, idiopathic hypersomnia with long sleep time; IHS w/o LST, idiopathic hypersomnia without long sleep time; OR, odds ratio.
